Navigation Links
VisEn Launches New Annexin-Vivo 750 Fluorescence Molecular Imaging Agent

BEDFORD, Mass., Sept. 2 /PRNewswire/ -- VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new Annexin-Vivo 750 imaging agent for measuring and monitoring apoptosis and cell death in vivo. The new Annexin-Vivo 750 agent is based on the well established Annexin labeling standard in in vitro research. It is expected to significantly expand research areas and enhance drug development by enabling real time imaging of apoptosis and cell death biomarkers associated with disease progression and therapeutic response in vivo.

Annexin-Vivo 750 targets membrane-bound phosphatidylserine exposed in the outer leaflet of the plasma membrane during the induction of apoptosis and cell death. The new agent was developed through an R&D collaboration with MosaMedix, a pioneer in the development of advanced Annexin V-based products. "Annexin is a gold standard in research for the detection of exposed phosphatidylserine, a hallmark of apoptotic and dying cells," said Kirtland Poss, VisEn's President and CEO. "VisEn and MosaMedix have worked closely together to develop a robust Annexin-based in vivo fluorescent imaging agent for the assessment of apoptosis and cell death in vivo. We expect this agent to open up truly breakthrough research areas, especially along with complementary in vitro readouts and within VisEn's broader fluorescence in vivo imaging agent portfolio." "We are extremely pleased to be working with VisEn, a clear leader in the field of in vivo fluorescent imaging and the perfect partner in enabling the new in vivo imaging applications using our Annexin V technology platforms," said Peter Moonen, CEO of MosaMedix.

VisEn's proprietary fluorescence imaging agents and labels are designed to provide the industry's broadest and most robust range of biologically-specific imaging readouts in vivo. VisEn now offers over 25 different fluorescence molecular agents for imaging key disease-associated biologic targets, processes and pathways. VisEn agent brands include ProSense(R), IntegriSense(TM), AngioSense(TM), OsteoSense(R), MMPSense(TM), Cat-K FAST(TM), and now Annexin-Vivo. VisEn also offers specialized lines of in vivo agent labeling platforms, including its proprietary VivoTag(R) fluorescence labeling dyes for custom agent development and its NanoSpark(R) labeling nanoparticles. They are all designed and optimized specifically for superior biocompatibility, brightness, stability and performance in in vivo imaging. All VisEn agents and labels, including the new Annexin-Vivo 750 and Cat-K FAST(TM) agents, are designed for in vivo biomarker quantification using VisEn's Fluorescence Molecular Tomography (FMT(TM)) imaging systems, or for general use along with other non-quantitative fluorescence in vivo imaging systems. VisEn agents are also designed to enable complementary in vitro biomarker readouts in cells and tissues using standard fluorescence microscopy and cellular-based imaging systems. With a focus on translational research and results, all of VisEn's technologies are designed to generate translational data linking pre-clinical research into clinical medicine.

About VisEn Medical Inc.

VisEn's in vivo fluorescence imaging technologies, including its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomography (FMT(TM)) Imaging Systems, provide robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo. VisEn's FMT systems and agents are used by leading research institutions and pharmaceutical companies worldwide in applications including cancer research, inflammation, cardiovascular, skeletal and pulmonary disease. The Company also works with large pharmaceutical and clinical partners to design ranges of tailored molecular imaging agents and applications designed for their specific pre-clinical and clinical research areas.

Additional information can be found at

About MosaMedix

MosaMedix has been established for the development of in vivo diagnostic and therapeutic products based on the Annexin Technology Platform that has potential applications in various medical fields, such as Oncology, Cardiovascular Medicine and Respiratory Medicine. The principals at MosaMedix have advanced the technology for in vitro utilization which has become a "golden standard" in Apoptosis Research. Based on recent discoveries and inventions the company is now focused on the translation of its proprietary technology into clinically valuable applications.

SOURCE VisEn Medical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. VisEn Launches New Cat-K FAST(TM) Fluorescence Molecular Imaging Agent
2. VisEn Launches Next-Generation Fast (Fluorescence Activatible Sensor Technology) Agent Platform for Expanded Performance in Imaging Disease Biomarkers In Vivo
3. VisEn Announces Commercial Launch of IntegriSenseTM Fluorescence Molecular Imaging Agent
4. VisEn Medical Raises $7 Million in Series B Financing
5. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
6. Actelion Launches Increased Strength Formulation of Ventavis (Iloprost) for Pulmonary Arterial Hypertension in the United States
7. OriGene Launches 5,000 Purified Human Proteins from HEK293 Cells
8. Elsevier Global Medical News Launches H1N1 Channel
9. PharmaTelevision Launches the First Daily News Show for the Life Sciences Industry
10. Surface Mount Solutions Launches New Website
11. One of the Nation's Leading Analytical Testing Laboratories is Now Easier to Access -- Pace Analytical Launches New Web Site to Showcase Its Three Business Divisions
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... IIROC on behalf of the Toronto Stock Exchange, confirms ... there are no corporate developments that would cause the ... --> --> About Aeterna Zentaris ... . --> Aeterna Zentaris is a specialty ...
(Date:11/24/2015)... , ... November 24, 2015 , ... The Academy of ... Interest Group (SIG), MultiGP, also known as Multirotor Grand Prix, to represent the First–Person ... few years. Many AMA members have embraced this type of racing and several new ...
(Date:11/24/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) ... remaining 11,000 post-share consolidation (or 1,100,000 pre-share consolidation) ... B Warrants") subject to the previously disclosed November ... 2015, which will result in the issuance of ... the issuance of such shares, there will be ...
(Date:11/24/2015)... ... November 24, 2015 , ... Creation Technologies ... being named to Deloitte's 2015 Technology Fast 500 list of the fastest growing ... a FDA-cleared, Class II medical device that speeds up orthodontic tooth movement by ...
Breaking Biology Technology:
(Date:10/29/2015)... Mich. , Oct. 29, 2015  Rubicon ... Genomics for U.S. distribution of its DNA library ... kit and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX ... enable the preparation of NGS libraries for liquid ... for diagnostic and prognostic applications in cancer and ...
(Date:10/27/2015)... 27, 2015 In the present market scenario, ... for various industry verticals such as banking, healthcare, defense, ... growing demand for secure & simplified access control and ... as hacking of bank accounts, misuse of users, , ... as PC,s, laptops, and smartphones are expected to provide ...
(Date:10/26/2015)... PALO ALTO, Calif. and LAS ... – Nok Nok Labs , an innovator in ... FIDO Alliance , today announced the launch of its ... the first unified platform enabling organizations to use standards-based ... authentication. The Nok Nok S3 Authentication Suite is ideal ...
Breaking Biology News(10 mins):